Managing paraneoplastic GABABR-related limbic encephalitis in a patient with a small cell lung cancer receiving an Immune-Checkpoint Inhibitor (ICI) therapy: description of a case report
This case highlights the difficulty and complexity of the diagnosis and management of this rare entity, particularly in cancer patients receiving ICIs. This report suggests also the potential efficacy of combining rituximab and tocilizumab and clearly demonstrates that a multidisciplinary approach, tailored to individual patient's response, is crucial for optimizing treatment outcome.
Authors
- Sara Polidori
- Francesca Plastino
- Marie Bénaiteau (ORCID: https://orcid.org/0009-0005-2347-6006)
- M. D. M. Cezar (ORCID: https://orcid.org/0000-0003-4829-9606)
- Louise Tyvaert (ORCID: https://orcid.org/0000-0003-0555-7150)
- Julie Egea
- Pierre‐Olivier Legros
- Giampaolo Tortora (ORCID: https://orcid.org/0000-0002-1378-4962)
- Raffaele Longo (ORCID: https://orcid.org/0000-0001-6090-2012)
- Marco Campitiello
- Rachele Belletto
- Lisa Soive
Institutions
- Agostino Gemelli University Polyclinic (IT)
- Centre d’Investigation Clinique Innovation Technologique de Nancy (FR)
- Hôpital Pierre Wertheimer (FR)
- Centre Hospitalier Régional de Metz-Thionville (FR)
Publication Details
- Journal
- BMC Neurology
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1186/s12883-025-04483-z
- Primary Topic
- Autoimmune Neurological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00